These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19095197)

  • 1. Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis.
    Poole D; Bertolini G; Garattini S
    Lancet Infect Dis; 2009 Jan; 9(1):67-72. PubMed ID: 19095197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa on trial.
    Tillotson GS
    Lancet Infect Dis; 2009 Jan; 9(1):2-3. PubMed ID: 19095188
    [No Abstract]   [Full Text] [Related]  

  • 3. Drotrecogin alfa: new preparation. For some cases of severe sepsis?
    Prescrire Int; 2003 Apr; 12(64):55-7. PubMed ID: 12674116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials in severe sepsis with drotrecogin alfa (activated).
    Laterre PF
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S5. PubMed ID: 18269692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
    Morris PE; Light RB; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S19-24. PubMed ID: 12521614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drotrecogin alfa Eli Lilly.
    de Jonge E
    IDrugs; 2002 Apr; 5(4):363-8. PubMed ID: 15565519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.
    Pastores SM
    Postgrad Med J; 2003 Jan; 79(927):5-10. PubMed ID: 12566544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drotrecogin alfa (activated) for severe sepsis.
    Drug Ther Bull; 2006 Jan; 44(1):5-8. PubMed ID: 16425899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.
    Eichacker PQ; Natanson C; Danner RL
    N Engl J Med; 2006 Oct; 355(16):1640-2. PubMed ID: 17050887
    [No Abstract]   [Full Text] [Related]  

  • 14. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint.
    Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M
    N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated protein C for the treatment of severe sepsis.
    Houston G; Cuthbertson BH
    Clin Microbiol Infect; 2009 Apr; 15(4):319-24. PubMed ID: 19416303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party.
    Angus DC
    Crit Care; 2012 Feb; 16(1):107. PubMed ID: 22309988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postregistration trials: should we? How do we?
    Del Sorbo L; Thompson BT; Ranieri VM
    Crit Care Med; 2009 Jan; 37(1 Suppl):S154-8. PubMed ID: 19104216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
    Laterre PF; Abraham E; Janes JM; Trzaskoma BL; Correll NL; Booth FV
    Crit Care Med; 2007 Jun; 35(6):1457-63. PubMed ID: 17452935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of drotrecogin alfa (activated) in severe sepsis: data from adult clinical trials and observational studies.
    Woodward B; Cartwright M
    J Crit Care; 2009 Dec; 24(4):595-602. PubMed ID: 19327331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.